Jinbei oral liquid for idiopathic pulmonary fibrosis: a randomized placebo-controlled trial
Abstract The traditional Chinese medicine compound preparation known as Jinbei Oral Liquid (JBOL) consists of 12 herbs, including Astragalus membranaceus (Fisch.) Bge, Codonopsis pilosula (Franch.) Nannf, et al. Having been used for over 30 years in the treatment of pulmonary diseases, JBOL was eval...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-01-01
|
| Series: | Scientific Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1038/s41598-025-87474-x |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832585795157884928 |
|---|---|
| author | Aijun Zhang Kangkang Han Fangfang Chen Xiao Chen Jun Wang Yikai Niu Zhaoqiu Hu Chunyan Zheng Liping Han Zhaoqing Meng Liangzong Zhang Qingcui Xu Cuixiang Yu Wei Zhang Quanguo Li Ningning Tao Weixiang Kong Fei Liu Min Wang Juanjuan Jiang Honglin Li LongBin Pang Huaichen Li |
| author_facet | Aijun Zhang Kangkang Han Fangfang Chen Xiao Chen Jun Wang Yikai Niu Zhaoqiu Hu Chunyan Zheng Liping Han Zhaoqing Meng Liangzong Zhang Qingcui Xu Cuixiang Yu Wei Zhang Quanguo Li Ningning Tao Weixiang Kong Fei Liu Min Wang Juanjuan Jiang Honglin Li LongBin Pang Huaichen Li |
| author_sort | Aijun Zhang |
| collection | DOAJ |
| description | Abstract The traditional Chinese medicine compound preparation known as Jinbei Oral Liquid (JBOL) consists of 12 herbs, including Astragalus membranaceus (Fisch.) Bge, Codonopsis pilosula (Franch.) Nannf, et al. Having been used for over 30 years in the treatment of pulmonary diseases, JBOL was evaluated in this study in order to assess its effect on idiopathic pulmonary fibrosis as well as its safety (ChiCTR2000035351, Chictr.org.cn.09/08/2020). A double-blind, multicenter, randomized, proof-of-concept trial was conducted to assess the efficacy of oral JBOL 40 ml and Corbrin Capsules 1 g compared to a placebo and Corbrin Capsules in patients with idiopathic pulmonary fibrosis (IPF). Over a 26-week period, patients received the active treatment or placebo three times daily, in a 1:1 ratio. This clinical study uses a randomized method, with a cycle of every 4 patients. TCM doctors at or above the deputy director level of the research center conduct TCM dialectics on IPF patients. To assess efficacy, over the duration of the trial, we measured serial changes in a composite indicator encompassing time to first acute exacerbation of IPF (first hospitalization or death due to respiratory cause), total lung capacity (TLC) (mL), predicted forced vital capacity (FVC%), forced vital capacity (FVC) (mL), predicted diffusing capacity of the lungs for carbon monoxide (predicted DLco%), 6-minute walk distance (6MWD), St. George’s Respiratory Questionnaire (SGRQ) total score, and arterial oxygen partial pressure (PaO2) from baseline to week 26 versus placebo. A total of 103 patients were screened, and 72 received the study medication. Of these, 68 patients were included in the analysis set, with 34 receiving JBOL and 34 receiving a placebo. After 26 weeks, a statistically significant reduction in total lung capacity (TLC) was observed for the JBOL group, with a change of 136 mL compared to -523 mL for the placebo group (difference 659 mL, 95% CI -1215 to -104 mL, p = 0.02). The study found that the change in FVC% predicted was − 1.48% and − 3.58% for the JBOL and placebo groups, respectively (difference of 2.10%, 95% CI -7.13 to 2.93, p = 0.41). Additionally the differences between the two groups in changes in FVC (mL), DLCO % predicted, PaO2 (mmHg) measures were − 67 mL (95% CI -238 to 104), -7.74% (95% CI -17.26 to 1.79), and − 3.57 mmHg (95% CI -10.02 to 2.87), respectively. Treatment with JBOL compared to placebo resulted in sequential changes in acute exacerbation, with no significant difference in SGRQ scores. It was not found that there was a statistically significant difference between the JBOL and placebo groups in TEAE reporting and serious TEAE reporting. Compared to the placebo group, there was a statistically significant reduction (p < 0.021) in TLC (mL) after 26 weeks for JBOL. The rates of FVC % predicted, FVC, DLCO % predicted, and PaO2 in the group treatment with JBOL were numerically lower than those in the placebo treatment group, although these differences did not reach statistical significance. JBOL exhibited comparable safety to placebo. This study has preliminarily shown the efficacy and safety of JBOL for IPF, but this is an exploratory clinical trial, more patient-involved studies should be needed in the near future. Trial registration: Chictr.org.cn ChiCTR2000035351; the trial was prospective clinical studies registered on August 9, 2020. |
| format | Article |
| id | doaj-art-a55607391df64d538eeff5cd2edd8b3d |
| institution | Kabale University |
| issn | 2045-2322 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj-art-a55607391df64d538eeff5cd2edd8b3d2025-01-26T12:29:28ZengNature PortfolioScientific Reports2045-23222025-01-0115111110.1038/s41598-025-87474-xJinbei oral liquid for idiopathic pulmonary fibrosis: a randomized placebo-controlled trialAijun Zhang0Kangkang Han1Fangfang Chen2Xiao Chen3Jun Wang4Yikai Niu5Zhaoqiu Hu6Chunyan Zheng7Liping Han8Zhaoqing Meng9Liangzong Zhang10Qingcui Xu11Cuixiang Yu12Wei Zhang13Quanguo Li14Ningning Tao15Weixiang Kong16Fei Liu17Min Wang18Juanjuan Jiang19Honglin Li20LongBin Pang21Huaichen Li22Shandong Hongji-tang Pharmaceutical Group Co., Ltd.Department of General Practice, Qilu Hospital of Shandong UniversityDepartment of Pulmonary and Critical Care Medicine, The first affiliated Hospital of Shandong First Medical UniversityDepartment of Pulmonary and Critical Care Medicine, Tai’an City Central HospitalDepartment of Pulmonary and Critical Care Medicine, The Second Affiliated Hospital of Shandong University of Traditional Chinese MedicineDepartment of Respiratory and Critical Care Medicine, Yidu Central Hospital of WeiFangDepartment of Pulmonary and Critical Care Medicine, Weifang Respiratory Disease HospitalDepartment of General Practice, Qilu Hospital of Shandong UniversityPulmonary and Critical Care MedicineShandong Hongji-tang Pharmaceutical Group Co., Ltd.Shandong Hongji-tang Pharmaceutical Group Co., Ltd.Shandong Hongji-tang Pharmaceutical Group Co., Ltd.Department of Pulmonary and Critical Care Medicine, The first affiliated Hospital of Shandong First Medical UniversityDepartment of Pulmonary and Critical Care Medicine, Tai’an City Central HospitalDepartment of Pulmonary and Critical Care Medicine, Weifang Respiratory Disease HospitalDepartment of Pulmonary and Critical Care Medicine, Jinan Central HospitalPulmonary and Critical Care MedicineDepartment of Respiratory and Critical Care Medicine, Yidu Central Hospital of WeiFangDepartment of Pulmonary and Critical Care Medicine, The Second Affiliated Hospital of Shandong University of Traditional Chinese MedicineShandong Hongji-tang Pharmaceutical Group Co., Ltd.Shandong Hongji-tang Pharmaceutical Group Co., Ltd.Department of Pulmonary and Critical Care Medicine, Jinan Central HospitalDepartment of Respiratory and Critical Care Medicine, Shandong Provincial Hospital Affiliated to Shandong First Medical UniversityAbstract The traditional Chinese medicine compound preparation known as Jinbei Oral Liquid (JBOL) consists of 12 herbs, including Astragalus membranaceus (Fisch.) Bge, Codonopsis pilosula (Franch.) Nannf, et al. Having been used for over 30 years in the treatment of pulmonary diseases, JBOL was evaluated in this study in order to assess its effect on idiopathic pulmonary fibrosis as well as its safety (ChiCTR2000035351, Chictr.org.cn.09/08/2020). A double-blind, multicenter, randomized, proof-of-concept trial was conducted to assess the efficacy of oral JBOL 40 ml and Corbrin Capsules 1 g compared to a placebo and Corbrin Capsules in patients with idiopathic pulmonary fibrosis (IPF). Over a 26-week period, patients received the active treatment or placebo three times daily, in a 1:1 ratio. This clinical study uses a randomized method, with a cycle of every 4 patients. TCM doctors at or above the deputy director level of the research center conduct TCM dialectics on IPF patients. To assess efficacy, over the duration of the trial, we measured serial changes in a composite indicator encompassing time to first acute exacerbation of IPF (first hospitalization or death due to respiratory cause), total lung capacity (TLC) (mL), predicted forced vital capacity (FVC%), forced vital capacity (FVC) (mL), predicted diffusing capacity of the lungs for carbon monoxide (predicted DLco%), 6-minute walk distance (6MWD), St. George’s Respiratory Questionnaire (SGRQ) total score, and arterial oxygen partial pressure (PaO2) from baseline to week 26 versus placebo. A total of 103 patients were screened, and 72 received the study medication. Of these, 68 patients were included in the analysis set, with 34 receiving JBOL and 34 receiving a placebo. After 26 weeks, a statistically significant reduction in total lung capacity (TLC) was observed for the JBOL group, with a change of 136 mL compared to -523 mL for the placebo group (difference 659 mL, 95% CI -1215 to -104 mL, p = 0.02). The study found that the change in FVC% predicted was − 1.48% and − 3.58% for the JBOL and placebo groups, respectively (difference of 2.10%, 95% CI -7.13 to 2.93, p = 0.41). Additionally the differences between the two groups in changes in FVC (mL), DLCO % predicted, PaO2 (mmHg) measures were − 67 mL (95% CI -238 to 104), -7.74% (95% CI -17.26 to 1.79), and − 3.57 mmHg (95% CI -10.02 to 2.87), respectively. Treatment with JBOL compared to placebo resulted in sequential changes in acute exacerbation, with no significant difference in SGRQ scores. It was not found that there was a statistically significant difference between the JBOL and placebo groups in TEAE reporting and serious TEAE reporting. Compared to the placebo group, there was a statistically significant reduction (p < 0.021) in TLC (mL) after 26 weeks for JBOL. The rates of FVC % predicted, FVC, DLCO % predicted, and PaO2 in the group treatment with JBOL were numerically lower than those in the placebo treatment group, although these differences did not reach statistical significance. JBOL exhibited comparable safety to placebo. This study has preliminarily shown the efficacy and safety of JBOL for IPF, but this is an exploratory clinical trial, more patient-involved studies should be needed in the near future. Trial registration: Chictr.org.cn ChiCTR2000035351; the trial was prospective clinical studies registered on August 9, 2020.https://doi.org/10.1038/s41598-025-87474-xIdiopathic pulmonary fibrosisTraditional Chinese medicineJinbei oral liquidClinical trial |
| spellingShingle | Aijun Zhang Kangkang Han Fangfang Chen Xiao Chen Jun Wang Yikai Niu Zhaoqiu Hu Chunyan Zheng Liping Han Zhaoqing Meng Liangzong Zhang Qingcui Xu Cuixiang Yu Wei Zhang Quanguo Li Ningning Tao Weixiang Kong Fei Liu Min Wang Juanjuan Jiang Honglin Li LongBin Pang Huaichen Li Jinbei oral liquid for idiopathic pulmonary fibrosis: a randomized placebo-controlled trial Scientific Reports Idiopathic pulmonary fibrosis Traditional Chinese medicine Jinbei oral liquid Clinical trial |
| title | Jinbei oral liquid for idiopathic pulmonary fibrosis: a randomized placebo-controlled trial |
| title_full | Jinbei oral liquid for idiopathic pulmonary fibrosis: a randomized placebo-controlled trial |
| title_fullStr | Jinbei oral liquid for idiopathic pulmonary fibrosis: a randomized placebo-controlled trial |
| title_full_unstemmed | Jinbei oral liquid for idiopathic pulmonary fibrosis: a randomized placebo-controlled trial |
| title_short | Jinbei oral liquid for idiopathic pulmonary fibrosis: a randomized placebo-controlled trial |
| title_sort | jinbei oral liquid for idiopathic pulmonary fibrosis a randomized placebo controlled trial |
| topic | Idiopathic pulmonary fibrosis Traditional Chinese medicine Jinbei oral liquid Clinical trial |
| url | https://doi.org/10.1038/s41598-025-87474-x |
| work_keys_str_mv | AT aijunzhang jinbeioralliquidforidiopathicpulmonaryfibrosisarandomizedplacebocontrolledtrial AT kangkanghan jinbeioralliquidforidiopathicpulmonaryfibrosisarandomizedplacebocontrolledtrial AT fangfangchen jinbeioralliquidforidiopathicpulmonaryfibrosisarandomizedplacebocontrolledtrial AT xiaochen jinbeioralliquidforidiopathicpulmonaryfibrosisarandomizedplacebocontrolledtrial AT junwang jinbeioralliquidforidiopathicpulmonaryfibrosisarandomizedplacebocontrolledtrial AT yikainiu jinbeioralliquidforidiopathicpulmonaryfibrosisarandomizedplacebocontrolledtrial AT zhaoqiuhu jinbeioralliquidforidiopathicpulmonaryfibrosisarandomizedplacebocontrolledtrial AT chunyanzheng jinbeioralliquidforidiopathicpulmonaryfibrosisarandomizedplacebocontrolledtrial AT lipinghan jinbeioralliquidforidiopathicpulmonaryfibrosisarandomizedplacebocontrolledtrial AT zhaoqingmeng jinbeioralliquidforidiopathicpulmonaryfibrosisarandomizedplacebocontrolledtrial AT liangzongzhang jinbeioralliquidforidiopathicpulmonaryfibrosisarandomizedplacebocontrolledtrial AT qingcuixu jinbeioralliquidforidiopathicpulmonaryfibrosisarandomizedplacebocontrolledtrial AT cuixiangyu jinbeioralliquidforidiopathicpulmonaryfibrosisarandomizedplacebocontrolledtrial AT weizhang jinbeioralliquidforidiopathicpulmonaryfibrosisarandomizedplacebocontrolledtrial AT quanguoli jinbeioralliquidforidiopathicpulmonaryfibrosisarandomizedplacebocontrolledtrial AT ningningtao jinbeioralliquidforidiopathicpulmonaryfibrosisarandomizedplacebocontrolledtrial AT weixiangkong jinbeioralliquidforidiopathicpulmonaryfibrosisarandomizedplacebocontrolledtrial AT feiliu jinbeioralliquidforidiopathicpulmonaryfibrosisarandomizedplacebocontrolledtrial AT minwang jinbeioralliquidforidiopathicpulmonaryfibrosisarandomizedplacebocontrolledtrial AT juanjuanjiang jinbeioralliquidforidiopathicpulmonaryfibrosisarandomizedplacebocontrolledtrial AT honglinli jinbeioralliquidforidiopathicpulmonaryfibrosisarandomizedplacebocontrolledtrial AT longbinpang jinbeioralliquidforidiopathicpulmonaryfibrosisarandomizedplacebocontrolledtrial AT huaichenli jinbeioralliquidforidiopathicpulmonaryfibrosisarandomizedplacebocontrolledtrial |